Compare Bristol-Myers Squibb Co (BMY) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Abrdn Physical Platinum Shares ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.81 (market cap $132.45B), while Abrdn Physical Platinum Shares ETF trades at $15.88. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Abrdn Physical Platinum Shares ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| BMY | PPLT | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $65.89 | $25.23 |
52-Week Low | $42.60 | $11.95 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
PPLT trades at $15.85, up 1.15% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock is set for a 1:10 stock split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, positioning PPLT as a potential catch-up trade in the precious metals sector.
The outlook for PPLT hinges on a potential rebound in platinum prices, supported by positive sentiment from recent geopolitical developments. Key risks include continued commodity price volatility and the ETF's lack of dividend income, which may deter yield-seeking investors despite its strong past performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
